Potential Research Questions
Which are early events in the pathogenesis of cardiometabolic diseases?
Which factors define clinical outcomes of patients with cardiovascular disease?
How can the best treatment be chosen?
For more information on a specific indication, please read more here:
Status Quo and Medical Need
A significant proportion of patients affected by or people at risk for cardiometabolic diseases are undiagnosed. Treatment refractory disease and rising health care costs are also matters of concern. The finding that health promoting and disease preventing lifestyle interventions need to be highly individualized, further highlight the need for new and better biomarkers.
Metabolic phenotyping has been playing a large role in developing promising markers at any stage of cardiometabolic diseases– whether it‘s prediction, diagnosis, or disease monitoring. Metabolic research has also helped in understanding the pathophysiological mechanisms involved, and will continue to do so. Biocrates’ focus on low sample requirement, high throughput and reproducibility facilitates bench-to-bedside research strategies.
Relevant Metabolite Classes
Amino acids and biogenic amines:
- Amino acids are strong predictors of outcome in heart failure.
- Branched chain amino acids (BCAA) are involved in early diabetes pathogenesis.
Phospho- and sphingolipids:
- The LDL lowering effect of metformin occurs through changes in phospholipid metabolism.
- Lipid signatures identify metabolically healthy obese, as well as metabolically unhealthy lean individuals.
- Steroid hormones are involved in regulating glucose metabolism and blood pressure.
- Multiple steroid hormones are known to affect cardiovascular outcome.
- Bile acids link gut microbiome and diabetes.
- Bile acids are a major component of lipoproteins and may affect their size and function.
- Oxysterols are thought to be a major contributor to the detrimental effects of altered cholesterol metabolism.
- Ryan et al.: Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E(-/-) mice; Microbiome 2017
- Ward-Caviness et al.: Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers; Heart 2017
- Feldman et al.: Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver; The American journal of gastroenterology 2016
- Cheng et al.: Metabolic Disturbances Identified in Plasma Are Associated With Outcomes in Patients With Heart Failure; JACC 2015
- Geurts et al.: Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota; Nature Communications 2015
- Xu et al.: Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes; Diabetes Care 2015
- Zwadlo et al.: Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction; Circulation 2015
For more information, please contact us!
For Research Use Only. Not for use in diagnostic procedures.